ArticleFrontiers in cell and developmental biology2021
The Effect of Smoking on the Immune Microenvironment and Immunogenicity and Its Relationship With the Prognosis of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer.
Article in Frontiers in cell and developmental biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Adjuvant immune checkpoint inhibitors in early-stage non-small cell lung cancer: insights from a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Pooled it
- The Promise of Chemotherapy-Free Strategies in Advanced Driver-Negative NSCLC: A Systematic Review and Network Meta-Analysis of Antiangiogenic Combination Therapies.Cancer medicine · 2026Pooled it
- Pooled it
- First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial.Journal for immunotherapy of cancer · 2024Trial
- Differential Treatment Effects by Smoking Status for NSCLC Therapies (2010-2023): A Meta-Analysis.JTO clinical and research reports · 2026Article
- Risk modifiers of immune-related adverse events in patients with NSCLC undergoing immunotherapy: a retrospective cohort study.Journal of pharmaceutical health care and sciences · 2026Article
- Evaluation of smoking status as a prognostic factor under immune checkpoint inhibitor treatment: A single center analysis.Oncology letters · 2026Article
- Unraveling the molecular mechanisms of smoking-associated non-small cell lung cancer: a comprehensive analysis of genetic, therapeutic, and immunological.Journal of thoracic disease · 2026Article
- The tumor microenvironment in esophageal cancer and its association with clinical features and neoadjuvant treatment response.Scientific reports · 2026Article
- Real-world insights into incidence and risk factors of thyroid dysfunction following immune checkpoint inhibitor therapy.Frontiers in immunology · 2026Observational
- An exploratory study of BLCA-4 expression, STR analysis, and urothelial cytology in smokers versus non-smokers with bladder cancer.Frontiers in oncology · 2026Article
- The pathogenic mutations in smokers with non-small cell lung cancer: a next-generation sequencing study.Translational lung cancer research · 2025Article
- Tumour and microenvironment crosstalk in NSCLC progression and response to therapy.Nature reviews. Clinical oncology · 2025Review
- Efficacy and safety of first-line chemoimmunotherapy in young patients with extensive-stage small cell lung cancer: a multicenter retrospective study.BMC cancer · 2025Article
- Article
- Review
- Prognostic value of liver metastasis in patients with esophageal squamous cell carcinoma treated with nivolumab.Oncology letters · 2025Article
- Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASAnnals of oncology : official journal of the European Society for Medical Oncology · 2025Article
- Circulating white blood cell traits, chemokines and small cell lung cancer risk: a Mendelian randomization study.Translational cancer research · 2025Article
- Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.